Valeant investor sues over Biovail deal; Italy plans cuts to generic-drug prices;

 @FiercePharma: With Aspen circling, Sigma gets piecemeal bids. Article | Follow @FiercePharma

> Valeant Pharmaceuticals' $3.2 million merger with Biovail shortchanges Valeant investors while enriching the company's executives, a shareholder said in a lawsuit. Story

> From next year, the maximum reimbursement paid for generic drugs by the Italian health service (SSN) will be based on the drugs' average prices in Europe, a move the government says will save around €600 million. Article

> Biogen Idec said its profit more than doubled in the second quarter compared to a year ago, when it entered a partnership on a potential multiple sclerosis drug. Report

> Australian vaccine maker CSL says its new $235 million plant will advance development of its portfolio of biotech cancer drugs, anti-infectives and plasma products. Report

> Europe's largest biotech company, Actelion (ATLN.VX), raised its 2010 earnings goal and posted stronger-than-expected sales of key heart and lung drug Tracleer. News

> Shares of King Pharmaceuticals rose Monday after a Goldman Sachs analyst upgraded the drug developer, citing an improved risk-reward profile. Article

> Shares of Perrigo fell Monday after a Goldman Sachs analyst downgraded the over-the-counter drug maker, saying the stock has become expensive. Story

> Emergent BioSolutions says additional biomanufacturing space at its Baltimore, MD, plant could help reduce expenditure through use of new timesaving manufacturing tech. Story

Biotech News

 @FierceBiotech: Ramius looks to buy out Cypress. Article | Follow @FierceBiotech

> Actelion gets option to buy Trophos for up to $250 million. Story

> FDA accepts Mannkind's response, sets PDUFA date. News

> Ireland mulls $6B biopharma center. Report

 Biotech Research News

> Researchers combat aging as a "stem cell disease." News

> Scotland looks to beef up life sciences sector. Report

> iPSC use may be limited by 'memory'. Item

> Merck R&D site closure a blow to Canada. Story

> Researchers plan to use iPS cells to combat Parkinson's. Article

Manufacturing News

> Laid off McNeil plant workers can bid for other J&J jobs. Story

> Stability tests prompt Bausch & Lomb ReNu recall. Article

> UK regulator sounds cold chain alarm. Item

And Finally... WHO's emergency committee may convene next week to determine whether the H1N1 flu pandemic is ending. Report

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.